GNFT - GENFIT - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

217.1M

Cash

77.79M

Avg Qtr Burn

-13.86M

Short % of Float

0.16%

Insider Ownership

0.00%

Institutional Own.

0.21%

Qtr Updated

12/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Iqirvo® (elafibranor) Details Primary biliary cholangitis, Liver disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VS-01 Details Acute-on-Chronic liver failure, Liver disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nitazoxanide (NTZ) Details Non-alcoholic steatohepatitis , Acute-on-Chronic liver failure, Liver disease	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GNS561 Details Liver disease, Cholangiocarcinoma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Iqirvo® (elafibranor) Details Non-alcoholic steatohepatitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.